Ratings Ipca Laboratories Limited Bombay S.E.

Equities

IPCALAB

INE571A01038

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-04-26 am EDT			5-day change	1st Jan Change
1,339 ^INR	+0.82%		+0.14%	+20.23%

Mar. 29	Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director	CI
Mar. 29	Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
The company's profit outlook over the next few years is a strong asset.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.

Weaknesses

With an expected P/E ratio at 54.29 and 35.57 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
With an enterprise value anticipated at 4.62 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
IPCA LABORATORIES LIMITED	+20.23%	4.07B	C+
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes